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Androgenic alopecia (AGA), commonly known as pattern baldness, along with 
“loss of hair” following chemotherapy induced alopecia (CIA) are widespread maladies 
with treatments of little to no effectiveness. Following the discovery of a novel 4.2-kDa 
peptide’s (murikal/SPR4) ability to markedly increase hair growth when injected 
intradermally in wild type mice, liposomal topical formulations were developed and 
optimized to facilitate greater follicular delivery of the therapeutic peptide. Significant 
enhancement of hair growth rate was seen in mice treated with the peptide and liposomal 
vehicle when compared to commercial minoxidil (Rogaine®) formulations and peptide 
alone. An array of lipid formulations and preparation protocols were screened for 
follicular penetration efficiency utilizing biotinylated or fluor-labeled peptide and 
confocal microscopy. Two lead formulations were selected for a month long stability 
study of particle and peptide integrity. Each lead formulation showed near constant 
retention of encapsulated peptide. Formulation 3 showed a steady profile of ideal particle 
characteristics, particle size (~300 nm) and zeta potential (~70 mV), over the time period 
and temperatures tested. The two lead formulations were also applied ex-vivo to donor 
human scalp skin to determine translatability to a human follicle anatomy. Results of 
confocal microscopy imaging of treated human tissue were inconclusive on peptide 
penetration and follicle localization. Further testing is required to demonstrate 
translatability to human tissues. Overall, these results indicate the clear therapeutic 
potential of murikal formulated into an optimized liposomal solution for the treatment of 
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 Androgenic alopecia (AGA), commonly known as pattern baldness, is a 
widespread malady effecting nearly 50% of the Caucasian male and female populations 
by age 40 and reaching 80% by age 70 in men.1 Although with reduced prevalence, AGA 
is also found within other ethnicities. In addition, there is an unmet need for improved 
treatment of chemotherapy-induced alopecia (CIA) where hair loss occurs in 65% of 
treatments.2 While not directly life threatening, the potential psychological effects of hair 
loss in both male and females is of the utmost concern as patients experiencing hair loss 
have reported increased stress levels, lower self-esteem, and particularly at younger ages, 
poor body image perception.1, 3 Current treatments beyond surgical methods, including 
topical treatment with minoxidil or finasteride, the active ingredients found in Rogaine® 
and Propecia® respectively, have shown limited efficacy in restoring hair growth or 
slowing hair loss.4 The widespread prevalence of AGA and CIA combined with their 
associated negative psychological burdens and poorly effective treatment options 
indicates a dire need for a new and efficient therapeutic to treat these conditions. 
 In this study, a novel peptide therapeutic, which was observed to increase rates of 
hair growth in mice when injected intradermally, was formulated into a lipid nanoparticle 
formulation for efficient topical delivery to the hair follicle and to explore its therapeutic 
potential to treat AGA, CIA and other hair loss disorders. 
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2. Background 
2.1 Hair growth cycle and follicle biology 
Initial hair follicle development and maturation involves a complex network of 
regulatory signals between the developing dermal mesenchyme and epithelium during 
gestation, and the details are not yet well understood, specifically those involving 
initiation. Once the follicle has matured, normal hair growth cycles through defined 
stages: anagen (growing phase), catagen (regression phase) and a telogen (resting phase). 
The duration of each stage is dependent on follicle size and location, but under normal 
conditions 85% of scalp hair is within the anagen phase, lasting on average 2-6 years.5 
The total cycle is controlled by an array of cell signaling molecules and pathways 
involving cytokines, hormones and neurotransmitters targeting the proliferation of 
keratinocytes located at the bulb of the hair shaft.1  
Anatomically, the hair follicle complex is termed the pilosebaceous unit (Figure 
1) and is comprised of the hair follicle, sebaceous gland and arrector pili muscle.  
Located at the base of the hair shaft is the hair bulb, which rests on the dermal papilla. 
The dermal papilla and the proliferating keratinocytes are supplied nutrients via an 
underlying capillary. 
 
2.2 Androgenic (AGA) and chemotherapy-induced (CIA) alopecia 
Androgens are a general term for compounds, usually steroid hormones such as 
testosterone, which control development of male associated traits. Although the detailed 












duction, including Follistatin, and Gremlin, are also 
expressed in developing follicles. The apparently very 
complex interplay between activators and inhibitors of 
hair follicle formation, and the respective regulators of 
activator and inhibitor product expression likely deter-
mine the distribution of follicles in the skin [81].
With the development of hair follicles underway, yet 
more factors are required to regulate the hair germ in its 
growth and differentiation. Platelet-derived growth fac-
tor A (PDGFA) and Sonic hedgehog (Shh) are secreted 
by the ectodermal cells of the developing hair follicle. 
They are required for the condensation of the presump-
tive dermal papilla cells and for progression of the fol-
licle placode to the peg/bulge hair stages. Asymmetric 
expression of Shh also polarizes the hair, ensuring out-
growth of the hair follicle in a defined direction. While 
activin βa can act as a placode inhibitor, activin βa in 
combination with Shh, hepatocyte growth factor (HGF) 
and its receptor (MET), transcription factor SOX18, and 
TGFα have been identified as driving factors during or-
ganogenesis. These and other products impel the down-
growth of the hair germ into the dermis. In stages 5–8 
of hair follicle morphogenesis, the follicle differentiates 
into the complex structures that make up a mature hair 
Fig. 1.2 Anatomy of the pilosebaceous unit. All hair follicles follow a common ar-
chitecture. Together with the sebaceous gland (SG) and the arrector pili muscle (M), 
the hair follicle is part of the so-called pilosebaceous unit. The fibrous sheath (FS) 
and the epithelial outer and inner root sheaths (ORS, IRS) form concentric lay-
ers, which ensheath the hair shaft (HS). Hair growth results from the proliferative 
activity of matrix keratinocytes in the bulb, which sit on the dermal papilla (DP). 
The dermal papilla is a condensate of specialized mesenchymal cells with important 
inductive properties. It also provides nutrition via a capillary loop (C), which is es-
pecially prominent in terminal hair follicles. The permanent, superficial component 
has to be differentiated from the transient cycling component of the hair follicle, 
which includes the bulb. The morphological dividing line between these two com-
ponents lies below the bulge (B) region and the insertion of the arrector pili muscle 
(M). The size and shape of the hair follicles, however, vary with body location and 
potential functions. In anagen phase, for example, vellus hair follicles from the ret-
roauricular region (left) are approximately six times shorter than scalp hair terminal 
follicles (right). Each hair follicle has characteristic features. Vellus hair shafts, in 
contrast to terminal hair shafts, are usually devoid of a medulla (MD). Skirt-like 
epithelial structures (*), however, can only be found in vellus hair follicles
4 A. Vogt, K. J. McElwee, U. Blume-Peytavi  
1
Figure 1. Human pilosebaceous unit. From top: (SG)-sebaceous gland, 
(M)-arrector pili muscle, (HS)-hair shaft, (DP)-dermal papilla, (C)-
capillary. Adapted from Blume-Peytavi,	U.,	Whiting,	D.	A.	&	Trüeb,	R.	M.					
XXVI,	564	 Springer-Verlag	Berlin	Heidelberg,	2008).  
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particularly that of dihydrotestosterone (DHT), is commonly accepted. DHT is the 5α-
reduced version of testosterone and has been identified as a key factor in the induction of 
androgen dependent balding in some patients.6 Although abnormal DHT and other hair 
growth signaling molecules indicate a strong potential for the onset of baldness, these 
abnormalities alone are not solely responsible for development of AGA. In addition, 
genetically inherited predispositions within 5α-reductase and androgen receptor genes 
among others as well as age related alterations in androgen controlled mechanisms need 
to be considered.1 
CIA, which is also referred to as dystrophic anagen effluvium, is characterized by 
diffuse hair loss following chemotherapeutic cancerous tumor treatment as a result of the 
direct toxic effects on rapidly dividing bulb matrix cells found at the dermal papilla. Like 
AGA, CIA hair loss is first characterized by miniaturization of the follicle leading to 
thinning and shortening of the hair, prior to entering the telogenic phase where the hair is 
excluded from the follicle. Fortunately, after cessation of treatment, patients regain near 
full operation of their pre-treatment anagenic cycle and thus regain hair length and 
thickness. 1, 2 
 
2.3 Current treatment options for AGA and CIA 
Currently, two main compounds exist for the treatment of AGA associated pattern 
baldness, minoxidil and finasteride. Minoxidil, the active ingredient found in Rogaine®, 
has a mostly unclear mechanism of action, but it is believed to activate follicles at later 
stages in the growth cycle into the androgenic phase through its vasorelaxant effect. A 
10-12% increase in target area hair counts is seen with patients using the 5% formulation 
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with no increase in hair shaft thickness.1 Minoxidil is currently marketed as a topical 
solution and a foam-based formulation. The twice daily recommended dose of minoxidil 
has shown adverse effects including nausea and other systemic associated toxicity 
including cardiotoxicity and dyspnea.7 
Unlike minoxidil, finasteride acts to counter alopecia related disorders through 
inhibition of type 2 5α-reductase, the enzyme required to convert testosterone to DHT. 
Daily oral doses (1 mg) have shown efficacy in slowing baldness and 66% of patients 
have reported improved hair growth after about 12 months of treatment.8 Although 
treatment with finasteride has not been shown to regrow lost hair, inhibition and reversal 
of follicle miniaturization associated with androgenic alopecia has been observed. 
Adverse effects of oral dosage forms of finasteride mainly include an increased risk of 
sexual dysfunction.9, 10 
In regard to the treatment of CIA, preventative minoxidil treatment of patients 
undergoing early stages of chemotherapy showed limited capacity to prevent hair loss 
when compared to placebo.2, 11 Specific trials on the effect of finasteride to prevent 
chemotherapy-induced alopecia were not found. 
 
2.4 Murikal (SPR4-peptide) promotes Wnt/β-catenin pathway and 
subsequent hair growth 
 SPR4 or murikal is a recently described 4.2-kDa synthetic PHEX-peptide 
observed to bind and neutralize ASARM-peptides in addition to its positive effects on 
bone development (Sequence in Figure 2). Much of murikal’s positive effects can be 
contributed to its inhibition of sclerostin (SOST).12-17 Of interest to this application, 
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sclerostin is a known inhibitor of the Wnt β-catenin canonical pathway, which is a 
prominent signaling pathway for both early hair follicle formation18 as well as the 
induction of new hair growth cycles.1 The proposed mechanism of action is depicted in 
Figure 2. Proof of concept for murikal as a potential hair growth therapeutic was further 
demonstrated following daily intradermal injections of the peptide for 11 days (Figure 3). 
The mice shown in Figure 3 were of wild-type (C57BL/6) with complete depilation of 
their dorsal hair with Wax Strips (Del Laboratories,Farmingdale, NY) prior to the peptide 
treatment. 
 
2.5 Lipid nanoparticles for improved topical delivery of macromolecules 
 In response to the encouraging results seen after daily intradermal injections of 
murikal in mice to induce increased hair growth rates, a topical approach was explored to 
remove the need for injections and provide a more efficient and possible more effective 
targeted therapy to the follicle structure. 
 Lipid nanoparticles and particularly liposomes have been used for a wide range of 
drug delivery applications and compounds. A liposomal formulation is a promising 
delivery method for this application in that a wide variety of compounds may be 
encapsulated in the amphipathic particles, they may provide additional chemical stability 
to the peptide, liposomes induce little to no off-site toxicity, and most importantly, 
liposomes may be tuned to fit a wide variety of physicochemical environments providing 
a carrier with compatible properties to the highly lipophilic environment at the outer 











Figure 2. Proposed mechanism of murikal on increasing hair growth rate. Murikal 
inhibition of sclerostin (SOST) (9) and its downstream blockade (10) of Wnt and its 
association with the FRZ/LRP5/6 receptor complex (1). Activation of this complex 
leads to inhibition of GSK3β (2), which is responsible for the removal of cytoplasmic 
β-catenin through ubiquitin mediated proteolysis following phosphorylation (3). 
Higher levels of cytoplasmic β-catenin reduces the negative effects of DHT 
deactivation of β-catenin following the reduction of testosterone via excess 5-α 
reductase (6) and binding with androgen receptors (7 & 8). Overall leading to 
increased nuclear translocation of β-catenin (4) and increased transcription of factors 






















Figure 3. Wild type mice (C57BL/6) at Day 0 with treatment area hair removed 
with complete depilation and at Day 11 following daily intradermal injections of 
murikal (SPR4-peptide) or buffer control. Results obtained by Dr. Peter Rowe and 
reproduced with permission. 
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Many different active drugs, both small and large molecule, have been targeted to 
hair follicles with liposomal carriers of various compositions. Pairing a liposomal 
formulation to an active ingredient (API) is a balance of matching physicochemical 
properties to yield high and efficient encapsulation of the API, while also yielding 
particle biophysical properties that give optimum deposition into the targeted 
environment of the follicle. Successful liposomal delivery of drugs to follicles includes 
non-ionic20-22, cationic23, 24 and anionic25-27 formulations developed by various 
manufacturing methods.7, 28-31 
 In this study, murikal was initially formulated into a phosphatidylcholine (PC) 
based liposomal formulation and delivered topically to mice to show both qualitatively, 
via confocal microscopy imaging, and quantitatively, via pixilation of hair growth, the 
peptide’s potential as a topically delivered therapeutic. Once shown to be successful, 
formulations of various compositions were gathered from successful literature attempts 
and similarly tested by confocal microscopy for optimal performance. Two lead 
formulations were chosen from this study and subjected to a 30-day stability study of 
particle stability, drug release and drug degradation. These two lead formulations were 
finally applied ex-vivo to human donor facial tissue to determine deposition translatability 









L-α-Phosphatidylcholine (PC) from dried egg yolk, Type X-E, >=40% 
(enzymatic), Cholesterol (CH), 95%, α-Tocopherol (α-Toco), 96%, Dilaurin Mixed 
Isomers (GDL, Glyceryl dilaurate), Brij S10 (Polyethylene glycol octadecyl ether, 
Polyoxyethylene (10) stearyl ether) (POE-10), and Phytonadione, Vitamin K1 were 
purchased from Sigma-Aldrich Co (St. Louis, MO, USA). 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP) (chloride salt) was purchased from Avanti Polar 
Lipids (Alabaster, AL, USA). Murikal (SPR4-peptide), 80%, and Biotinylated-murikal 
were synthesized by PolyPeptide Laboratories (San Diego, CA, USA), sequence in 
Figure 2. Double distilled water (ddH2O) was used in the syntheses and characterization 
of the lipid particles. Tris Base and Sodium chloride were purchased from Fisher 
Scientific (Pittsburgh, PA, USA). Ethanol, 200 Proof, was obtained from Decon 
Laboratories, Inc.. All other solvents were of HPLC grade and obtained from Fisher 
Scientific. Table 1 outlines all liposomal formulations used and their adapted sources. 
Men’s Rogaine® Extra Strength, 5% Minoxidil Topical Solution, Unscented was 
purchased from a local pharmacy. 
 Alexa Fluor 594 (red) #S32356 and 488 (green) #S32354 were purchased from 
Molecular Probes (USA). DyLight™ 488 (Amax 493 nm, #53024) and Fluorescein 
isothiocyanate (FITC) antibody labeling kits were purchased from Thermo Scientific; 
























1 PC;EtOH28 100 103.8 4.3% 
2 PC/CH/DOTAP/α-












Toco;EtOH20, 21, 32 
50/14/23/12/1 50 0% 
5 GDL/CH/POE-10/DOTAP/ 
α-Toco;EtOH20, 21, 32 
50/14/23/12/1 50 4.3% 
* α-Tocopherol (α-Toco) replaced with Phytonadione, Vitamin K1, prior to ex-vivo 
human tissue trials due to reports of toxicity. 
Table 1. Liposomal formulations screened for optimum delivery of murikal to follicle 
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3.2 Methods 
3.2.1 Preparation of murikal encapsulated liposomes 
Egg phosphatidylcholine liposome formulation (F,1) was made by a modified 
ethanol injection method described elsewhere.28 Briefly, L-α-Phosphatidylcholine (2.39 
g/mL) was dissolved in ethanol. The solution was vortexed for 5 minutes and sonicated 
for 10 minutes or until a clear solution was achieved. Subsequently, murikal, 
biotinylated-murikal or fluorescently labeled-murikal (5 mg/mL) was dissolved in 25 mM 
Acetic acid at 1mg/100ul. Once dissolved, 50 mM Tris pH 7.4/150 mM NaCl was added 
drop wise to a peptide concentration of 5mg/mL The murikal solution was added drop 
wise (1.5 mL/h) to the lipid ethanolic solution using a syringe pump while constantly 
stirring. Then additional 50 mM Tris pH 7.4/150 mM NaCl (3.8X to murikal solution 
volume) was added drop wise (1.5 mL/h) using a syringe pump while constantly stirring. 
The final solution was stored at 4°C and covered from light exposure. The final 
formulation contained 103.8 mg/mL of lipid, 4.3% (v/v) of ethanol, and 0.99 mg/mL of 
murikal. Ethanol at up to 4.3% (v/v) was used within the formulation as a penetration 
enhancer, above this level would potentially cause unwanted irritation or redness when 
applied. 
 Formulations 2-5 (F,2-5) in Table 1 were prepared similarly to the PC liposome 
protocol above with slight modifications. All formulations were prepared using variations 
of the ethanol injection method due to its simplicity and verified efficacy from the first 
generation formula. The following example applies to (F,2-5) with specified lipids and 
solvent systems seen in Table 1. For F,3, L-α-Phosphatidylcholine/Cholesterol/1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP)/ α-Tocopherol were dissolved in 
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ethanol to 125 mg/ml with a molar ratio of 55.7:34.3:8.6:1.3, PC:CH:DOTAP: α-
Tocopherol. The solution was vortexed for 5 minutes and sonicated for 10 minutes or 
until a clear solution was achieved. Murikal (1.73 mg/mL) was dissolved in 25 mM acetic 
acid with subsequent addition of 50 mM Tris pH 7.4/150 mM NaCl, pH 7.4 (1:9, 
AcOH:Tris). The lipid ethanolic mixture was heated to 60°C for 2-3 min and the SPR4 
solution heated to 37°C for 2-3 min. The murikal solution was added drop wise to the 
lipid while constantly stirring until a 2:3 solvent-to-buffer ratio was achieved. 
Subsequently, organic solvents were removed by rotoevaporation entirely or to 4.3 % 
(v/v) (Organic solvent content of each formulation can be found in Table 1). Solvent 
removal continued until all foaming within the mixture ceased. The final solution was 
stored at 4°C and covered from light exposure. The final formulation contained 50 
mg/mL of lipid, 0% (v/v) or 4.3% (v/v) of ethanol and 0.99 mg/mL of murikal. 
 
3.2.2 Quantification of murikal encapsulated in liposomal formulation 
The amount of murikal incorporated into any of the liposomal formulations was 
quantified by the following method. A known volume of the final liposome solution was 
disrupted by a 10X dilution using dimethyl sulfoxide (DMSO) to determine total peptide 
content. A second vial of the same initial volume of the liposome solution was 
centrifuged at 13,300Xg for 15 min. The supernatant, unencapsulated murikal, was 
removed and placed in a new centrifuge cuvette and the pellet, encapsulated murikal, was 
retained. This procedure was repeated twice or until a pellet was no longer visible after 
centrifugation. The pellets were then combined and dissolved into enough dimethyl 
sulfoxide (DMSO) to match the volume of the total peptide vial. Both vials, total peptide 
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and encapsulated peptide, were subjected to 2 minutes of vortex mixing and 10 minutes 
of sonication. The concentration of murikal was determined in each by gradient RP-
HPLC against a known standard concentration profile. The HPLC system consisted of a 
Shimadzu LC-2010CHT (Shimadzu Scientific Instruments, Inc., Columbia, MA, USA) 
with in-line deuterium lamp ultraviolet detector. A Supelco Discovery HS C18 analytical 
column (150 × 4.6 mm; 3 µm) was used for the analysis. The mobile phase consisted of 
A (ddH2O, 0.1% formic acid) and B (acetonitrile, 0.1% formic acid), and the linear 
gradient was 10-100% B over 10 min at a flow rate of 0.8 mL/min. UV absorption was 
measured at 275 nm. The encapsulation efficiency (EE %) of murikal encapsulated into 
the liposome particle were calculated using the equation:  
EE % = (Corrected AUC of encapsulated (pellet) murikal/Corrected AUC of total 
murikal) ✕ 100%  
 
3.2.3 Particle size and zeta-potential measurements 
The hydrodynamic diameter of the liposomes was measured by dynamic light 
scattering (DLS) on a ZetaPALS (Brookhaven Instruments Corp., Holtsville, NY) 
following a 20X dilution in ddH2O, with stability analysis measurements of lead 
formulations repeated three times. Zeta potential of liposomes diluted 20X in ddH2O 
were measured on a ZetaPALS (Brookhaven Instruments Corp., Holtsville, NY), with 





3.2.4 Peptide mass spectrometry analysis 
 Mass spectrometry analysis was performed in conjunction with the KU Mass 
Spectrometry and Analytical Proteomics Laboratory using a Waters ACQUITY UPLC 
System coupled with a Thermo Finnigan ESI LQ-FTICR hybrid mass spectrometer. The 
RP-HPLC method used an Atlantis dC18 Column, 100Å, 3 µm (Waters Inc. P/N 
186001279), 5 cm, I.D. 1 mm with gradient elution of mobile phase consisting of A 
(ddH2O, 0.1% Formic acid) and B (9:1, Isopropanol:Acetonitrile, 10 mM Ammonium 
Formate, 0.1% Formic acid), with 1-50% B over 17 min and 50-95% over 2 min at 45-60 
µL/min . 
 
3.2.5 Murine ex-vivo peptide follicle penetration analysis 
 All experimental procedures were approved by the University of Kansas Medical 
Center, Institutional Animal Care and Use Committee (IACUC). Wild type mice 
(C57BL/6) were treated with liposomal solutions of a particular formulation following 
complete depilation of dorsal hair by Wax Strips (Del Laboratories,Farmingdale, NY) 
inducing premature anagen phase of the hair growth cycle. In the first trial using the first 
generation formulation (F,1), 50 µl of murikal labeled with DyLight™ 488 at 1 mg/ml 
was applied topically to the depilated region and allowed to absorb for 30 minutes prior 
to sacrifice. In the second trial where formulations were compared for optimum dermal 
penetration and follicle localization, 100 µl of biotinylated-murikal at 1mg/ml was 
applied topically to the depilated region and allowed to absorb for 10 minutes prior to 
sacrifice. In addition, tissue treated with a DermaRoller microneedle and subsequent 
aqueous peptide solutions (1mg/mL) were used to compare the follicular penetration 
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effectiveness of the liposomal formulation. Empty, no peptide, liposomes were used as a 
control. The treatment area was excised, and paraffin sections of 10% neutral buffered 
formalin (4% formaldehyde in phosphate buffered saline) fixed skin were prepared for 
histology and flash frozen in OCT and liquid nitrogen. Cryomolds were cryosectioned 
and stained with DAPI-Progold to visualize the nuclei of the cells. At this point, if 
biotinylated-murikal was initially applied, Alexa Fluor 488 or 594 streptavidin conjugates 
were also applied to the cryosectioned slides for peptide imaging. 
 
3.2.6 Murine in-vivo hair growth rate acceleration assessment 
 Anagen hair growth was induced on the dorsal surface of 5-week old wild type 
(C57BL/6) mice by wax strip treatment prior to application of the peptide formulations. 
Mice were treated with daily (50 µl) applications of murikal (1mg/ml) liposomal 
formulation, allowing 10 minutes for absorption. Similarly, minoxidil was applied daily 
at the manufacturer’s recommended doses. Empty, no peptide, liposome vehicles were 
applied at equal volumes and intervals to control treatment groups. Contrast images of 
hair growth were analyzed using a pixel conversion program, GelQuant.Net 
(BiochemicalLabSolutions.com).  
 
3.2.7 Lead formulations stability study 
 Two lead formulations were selected following analysis of murine follicle 
penetration of all formulations found in Table 1. Triplicate batches of each lead 
formulation were produced. Measurements of encapsulation efficiency of each batch 
were made on Day 0, 1, 2, 7, 14 and 28. Particle size and zeta potential of each batch 
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were measured on Day 0, 1, 9, 22, and 34. Results are expressed as average 
measurements with standard deviation. 
 
3.2.8 Human ex-vivo peptide follicle penetration analysis 
All experimental procedures were approved by the University of Kansas Medical 
Center, Institutional Review Board (Human Subjects Committee). Human donor scalp 
tissue following cosmetic surgery was treated with (10µl) of murikal (1mg/ml) liposome 
formulation spiked with 3.5 % (m/m) FITC-labeled peptide. Following 15 minutes or 30 
minutes of absorption time, 6 mm biopsy punches of the skin were made and flash frozen 
in OCT and liquid nitrogen. Cryomolds were cryosectioned and imaged by confocal 














4.1 Proof of concept: Liposomal topical therapeutic efficacy  
4.1.1 Murine ex-vivo peptide follicle penetration analysis 
DyLight™ 488 conjugated murikal was successfully encapsulated within a first 
generation egg phosphatidylcholine liposome formulation (F,1) at a concentration of 1 
mg/mL with an encapsulation efficiency of 71% (m/m) measured by RP-HPLC. 
Significant dermal penetration and follicular localization was observed by confocal 
analysis of treated tissue (Figure 4). Co-imaging of nuclei (DAPI-blue) and murikal 
(DyLight™ 488-green) 30 minutes after applying the formulation, indicate regions of 
specific cellular uptake of the peptide at deep portions of both the dermis and follicle as 
well as uptake within deep dermal neuronal cells (pacinian corpuscle). Buffer-only 
murikal solutions without lipid addition at 1mg/ml peptide were applied to the depilated 
dorsal skin of the mice, but sufficient peptide did not absorb for detection by confocal 
imaging. 
4.1.2 Murine in-vivo hair growth rate acceleration assessment 
 Daily application of F,1 with murikal at a concentration of 1 mg/mL and an 
encapsulation efficiency of 71% (m/m) resulted in quantifiably significant improvements 
in hair growth rate in wild type mice (C57BL/6) when compared to minoxidil and empty 
(no peptide) liposomal treatments (Figure 5). Digital quantification of contrast images of 
the treated areas (Figure 6) shows significant and major increases in the hair growth rate 
of mice treated with daily 50 µl topical application of the peptide liposome formulation 
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Figure 4. Confocal microscopy analysis of the dermal penetration of F,1. (a) Cross 
sectional diagram of skin with region of peptide specific cellular uptake and pacinian 
corpuscles noted, (b) histological cross section at 20X magnification and region of 
peptide specific cellular uptake noted, (c) 20X magnification confocal microscopy 
image of cryosectioned tissue treated with F,1, cells indicated by blue DAPI nuclear 
stain and DyLight™ 488-Murikal indicated in green, (d) 40X magnification confocal 


































































Figure 5. Accelerated hair growth seen in wild type mice treated with daily liposome 
formulations of murikal (50 µl) compared to minoxidil (Rogaine®) and empty (no 
peptide) liposome formulations. Anagen phase induced by complete depilation of 









Figure 6. Quantitative analysis of wild type mice at Day 14 of daily liposomal 
formulations of murikal following complete depilation of treatment area indicates 
significant and major increases in growth rate when compared to minoxidil and empty 
(no peptide) liposome control. Note, the lower the change in pixel density the greater 
the hair density.  
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4.2 Formulation optimization and ex-vivo murine screening 
 Four additional formulations as listed in Table 1 were adapted from the sources 
cited and applied topically to the depilated dorsal skin of wild type mice to assess their 
follicular penetration compared to F,1. All formulations when applied appeared visually 
as a milky white emulsion with viscosity near water. The encapsulation efficiency, size 
and zeta potential of each formulation are listed in Table 2. Confocal analysis indicated 
enhanced dermal penetration and follicular localization with F,3 and F,4 as compared to 
all other formulations used (Figure 7). Murikal dissolved in an aqueous buffer (no 
liposomes) and applied to depilated skin treated with a microneedle roller showed no 
significant dermal penetration or follicle localization. 
 
4.3 Lead formulations particle and peptide stability 
 F,3 and F,4 were advanced as lead formulations into a time and temperature 
dependent stability study, analyzing both the colloidal and chemical stability of the 
liposomes and peptide. 
 Encapsulation efficiency was monitored by centrifugal phase separation and 
subsequent peptide resolution by RP-HPLC. F,3 liposomal particles had an encapsulation 
efficiency of 83.73 ± 9.62 % (m/m) at Day 0, 86.66 ± 6.65 % after 28 days stored at 4°C, 
119.68 ± 20.55 % after 28 days stored at 25°C. F,4 liposomal particles had an 
encapsulation efficiency of 65.15 ± 22.80 % at Day 0, 104.05 ± 18.08 % after 28 days 
stored at 4°C, 95.72 ± 1.29 % after 28 days stored at 25°C (Figure 8).   
F,3 and F,4 liposomal particle sizes and zeta potential were monitored by dynamic 
light scattering and phase analysis light scattering of diluted samples with results shown 
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in Figure 9, 10, 11 and 12. F,3 liposomal particles had an effective diameter of 287 ± 18 
nm at Day 0, 328 ± 37 nm after 34 days stored at 4°C, 320 ± 48 nm after 35 days stored 
at 25°C. F,4 liposomal particles had an effective diameter of 2231 ± 1104 nm at Day 0, 
9180 ± 5947 nm after 35 days stored at 4°C, 17524 ± 11736 nm after 35 days stored at 
25°C. F,3 liposomal particles had a zeta potential of 74.25 ± 10.03 mV at Day 0, 74.94 ± 
11.27 mV after 34 days stored at 4°C, 81.03 ± 8.12 mV after 35 days stored at 25°C. F,4 
liposomal particles had a zeta potential of 4.08 ± 6.85 mV at Day 0, 66.97 ± 1.85 mV 
after 34 days stored at 4°C, -2.45 ± 9.28 mV after 35 days stored at 25°C. 
 Peptide stability was monitored using a Thermo Finnigan ESI LQ-FTICR hybrid 
mass spectrometer. Lyophilized murikal dissolved in 25 mM Acetic acid at 1mg/100ul 
and then diluted to 1mg/ml with 50 mM Tris pH 7.4/150 mM NaCl and immediately 
analyzed supported the manufacturer’s certificate of analysis spectrum with major species 
corresponding to peptide charge states at (M+3H)3+/3= 1631.1, (M+4H)4+/4= 1223.6, 
(M+5H)5+/5= 979.1 (Figure 13). After 40 days stored at 4°C and 25°C, F,3 and F,4 were 
diluted 5X in 200 proof ethanol and analyzed again for peptide mass. All major charge 
states as stated above in the parent peptide were within the spectra of the peptide 
associated peak at a tR=11 min (Figure 14). Similarly, major charged states of the parent 
peptide were seen within the spectra of both F,4 formulations stored at the two 
temperatures for one month (Figure 15). Unlike F,3, a co-eluting detergent is seen in the 
spectra of F,4, with a peak pattern at 500-1000 m/z in both conditions. This spectra is 
likely associated with the Dilaurin mixed isomers or polyethylene glycol octadecyl ether 
surfactants not found in F,3. Both sets of spectra at 25°C have an apparent lack in TIC of 
the parent peptide when compared to their 4°C counterpart. 
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4.4 Human ex-vivo peptide follicle penetration analysis 
 F,3 and F,4 with fluor-labeled murikal were applied to excised human facial tissue 
for 15 and 30 minutes and then flash frozen for confocal imaging. Confocal images of 
tissue treated with both formulations for 30 minutes in Figure 16 shows no significant 
dermal penetration or follicle localization of the fluor-murikal nor a general presence of 

























82.4 % 40,335 ± 
11,390 














84.1 % 1,667 ± 161 0.38 ± 0.04 4.74 ± 
5.19 
* α-Tocopherol (α-Toco) replaced with Phytonadione, Vitamin K1, prior to ex-vivo human 
tissue trials due to reports of toxicity. 
**Plus/minus indicate standard deviation from mean  
Table 2. Physical characterization of screened formulations to determine 
optimum dermal penetration and follicle localization of murikal peptide. 
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F4 F5 F3 
Figure 7. Confocal analysis of cryosectioned murine tissue treated with an array of 
formulations to optimize the dermal penetration and follicle localization of murikal. 
F,3 and F,4 taken as lead candidates. 
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 Figure 8. F,3 and F,4 liposome stored at 4°C and 25°C with peptide 
encapsulation efficiency % (EE %) measured at intervals for one 
month. Error bars indicate standard deviation from the mean. 
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Figure 9. F,3 and F,4 liposome stored at 4°C and 25°C with effective 
diameter measured at intervals for one month. Error bars indicate standard 
deviation from the mean. 

















































              
Figure 10. Logonormal distributions of F,3 and F,4 
effective diameters at Day 0 and after one month stored at 
4°C and 25°C. Each set represents data from all batches 
















































Figure 11. F,3 and F,4 liposome stored at 4°C and 25°C with 
zeta potential measured in intervals over one month. Error bars 
























Figure 12. Phase analysis light scattering (PALS) results from F,3 
and F,4 stored at 4°C and 25°C and measured for zeta potential at 















FML_20151026_770_1, SPR4_RM, 1 mg/ml
m/z






































Figure 13. Mass spectra of murikal dissolved in aqueous buffer at Day 0. Average 
molecular weight= 4891.2 per CoA, major species at (M+3H)3+/3= 1631.1, 
(M+4H)4+/4= 1223.6, (M+5H)5+/5= 979.1 
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FML_20151110_776_1, 3,4_E, 0.2mg/ml, SPR4 Formulation Stability 111015
m/z


























FML_20151110_776_2, 3,2_E, 0.2mg/ml, SPR4 Formulation Stability 111015
m/z































FML_20151110_776_1, 3,4_E, 0.2mg/ml, SPR4 Formulation Stability 111015
Time





















Figure 14. Mass spectra of murikal peptide after one month of storage within liposomal 
F,3 at 4°C (top) and 25°C (bottom). Mass spectra on peptide associated peak collected at 
tR=11 min (LC chromatogram, top insert). Average molecular weight= 4891.2 per CoA, 
major species at (M+3H)3+/3= 1631.1, (M+4H)4+/4= 1223.6, (M+5H)5+/5= 979.1 
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FML_20151110_776_3, 4,4_E, 0.2mg/ml, SPR4 Formulation Stability 111015
m/z





























FML_20151110_776_4, 4,2_E, 0.2mg/ml, SPR4 Formulation Stability 111015
m/z




































Figure 15. Mass spectra of murikal peptide after one month of storage within 
liposomal F,4 at 4°C (top) and 25°C (bottom). Average molecular weight= 








 Figure 16. Confocal and light microscope images (10X) of human facial tissue 
treated with (a) buffer only, (b) F,3 murikal-FITC loaded liposomes and (c) F,4 
murikal-FITC loaded liposomes for 30 minutes. Blue; DAPI-Progold stained 




5.1 Proof of concept: Liposomal topical therapeutic efficacy  
Results of F,1 suggested a strong potential for an efficient and targeted topical 
delivery of the murikal peptide to therapeutically relevant depths of the hair follicle at 
high concentrations (Figure 4). The hair growth acceleration observed in mice (Figure 5) 
replicated the observed therapeutic effect of the peptide seen after intradermal injections 
and also supports the substantial follicular delivery of the peptide within the liposomal 
formulation. In addition, the observed differences in hair growth rate between mice 
treated with the murikal formulation and those treated with minoxidil, which showed 
little effect compared to the controls, reaffirms murikal’s considerable therapeutic 
improvement on current treatment standards As seen in this study and the works adapted, 
liposomes are a promising tool for topical or transdermal delivery of small and large 
molecule therapeutics because they are able to encapsulate a wide range of hydrophilic 
and lipophilic therapeutics due to their amphiphilic composition and due to their 
membrane structure which serves to easily partition into the lipophilic environments 
found at the skin surface, dermis and pilosebaceous unit. 
 
5.2 Formulation optimization and ex-vivo murine screening 
Four additional formulations from successful literature trials of topical delivery of 
macromolecules were selected to screen against F,1 for optimum dermal penetration and 
follicle localization of the murikal peptide in its progression towards a human AGA and 
CIA therapy candidate. 
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Again following application to depilated mice skin and visualizing with confocal 
microscopy (Figure 7), F,3 and F,4 were identified as the most optimum due to their 
extensive murikal (red) dermal penetration and follicle localization. The particular 
success of F,3 and F,4 can likely be attributed to a number of factors identified in the 
characterization of the particles in Table 2. Like all other second generation formulations, 
F,3 and F,4 contained the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane, 
(DOTAP) (chloride salt), which according to previous studies25 and results in Table 2 
enhanced the zeta potential and thus particle stability to varying degrees above that of the 
first generation colloid. Zeta potential, measured in this study through phase analysis 
light scattering (PALS), represents the charge between the solid surface of a particle and 
the liquid solution. Zeta potential values > ±30 mV is the accepted threshold to 
preventing particle aggregation due to charge repulsion effects. In the particular case of 
F3 which had a measured zeta potential of 74.25 ± 10.03 mV, apparent increase in charge 
may have acted to stabilize particles through application and absorption into the dermis 
for optimal follicular delivery. Follicular localization of the positively charged particles 
may also be attributed to the anionic environment of the skin surface and hair itself 
leading to promotion of absorption through ion pairing mechanisms.25  
The enhanced dermal penetration and follicular localization of F3 may also be 
attributed to its effective diameter which was measured at 237 ±18 nm with a relatively 
monodisperse, low polydispersity index of 0.29, particle population compared to F,1 
which measured at a slightly larger particle diameter of 731 ± 16 nm. Previous studies33 
have indicated an optimum particle diameter in the hundreds of nanometer range for 
follicle delivery and storage.  
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The success of F,4 as defined by visual follicle localization in confocal images is 
harder to substantiate in that its charge is largely neutral and its particle size is well above 
1 µm. It is likely that if additional images were available for the similar, ethanol included, 
F,5, particularly images showing longitudinal sectioning of the pilosebaceous unit instead 
of latitudinal sectioning as seen in the images provided for F,4, near identical efficacy 
would be observed. However, it is apparent in the Figure 7 confocal images of F,3 and 
F,4 that optimum follicle penetration depth is achieved using the smaller, cationic F,3 
liposomal formulation. Reaching this target depth at or near the previously discussed bulb 
region where active keratinocyte proliferation occurs on the surface of the dermal papilla 
and thus hair growth induction may be critical to achieving an improved therapeutic 
effect. 
5.3 Lead formulations particle and peptide stability 
 Time and temperature dependent colloidal stability analysis of the lead 
formulations as observed through measurement of peptide encapsulation efficiency, 
particle size and zeta potential indicate clear differences in the integrity of the lipid 
nanoparticle carrier. F,3 was observed to gradually increase its encapsulation of peptide 
at 4°C and 25°C with the former approaching 86% (m/m) and the latter 100% (m/m) 
encapsulation by the end of the trial. Similarly, F,4 was observed to also increase its 
encapsulation of the murikal peptide over the month long study at both storage 
temperatures with each approaching 100% by trial’s end. Total peak area for all 
formulations at each storage temperature was observed to decrease over time as expected 
by either peptide precipitation or degradation. However, this decline cannot explain the 
measured increases in peptide uptake within the lipid phase of the system, particularly 
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measured values averaging above 100% (m/m) when done in triplicate. These results 
suggest possible systematic errors in the method development, sample preparation, or 
chromatogram integration. Although errors may exist in accurate quantification of this 
particle characteristic, relative conclusions may be drawn on the particles ability to 
encapsulate a majority of stable peptide into the lipid phase of the liposome formulation 
over a month of storage at the room temperature (25°C) and refrigerated (4°C) storage 
conditions. 
 Dynamic light scattering analysis (DLS) is a common method for measuring 
particle size and size distribution of a liposome populations. The DLS particle sizing 
range is a topic of continued debate, but its diameter accuracy is generally accepted from 
the low nanometer range to near one micron or higher depending on particle density and 
other factors such as sedimentation rate. The initial mean effective diameter of F,3 was 
near 300 nm while that of formulation 4 was greater than 2 µm. Polydispersity of both 
formulations initially suggest that formulation 3 is comprised of a much more 
monodisperse population of particles (PDI=0.29) compared to that of F,4 which had a 
PDI of 0.41. This difference in distribution is clearly visualized in the logonormal 
probability distributions across batches of both formulations at Day 0 and Day 35 after 
storage at the specified temperatures (Figure 10). Although the accuracy of particle sizing 
above 1 µm using DLS is highly sample dependent, particularly in the case of a more 
polydisperse or multimodal sample population such as that found in F,4, relative 
interpretation of the results can still be made. The liposomes found in F,3 showed near 
constant 300 nm mean effective diameter with relatively narrow population distributions 
when stored at both 4°C and 25°C over one month. F,4 DLS data indicated a particle at or 
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above 1 µm in effective diameter  with a wide, heterogeneous population distribution 
with similar consistency throughout the one month trial period at both 4°C and 25°C. 
This data indicates both formulations are of stable nature when tracking size while stored 
at various temperatures over a one month period. However, with optimum particle 
diameters defined in the hundreds of nanometers33 for follicle delivery at therapeutically 
relevant depths and questionable DLS data quality indicating possible particle 
aggregation or increased sedimentation rates of F,4, F,3 should be considered as the much 
more stable, definable, and therapeutically optimum based on particle size. 
 As discussed previously, zeta potential is related to the charge between a 
particulate surface and its liquid suspension. Ideal values are greater than ±30 mV in that 
higher charged systems should cause self-repulsion of similar charges leading to 
decreased particle aggregation and thus higher stability. Again F,3 is indicative of a more 
stable system in this regard due to its higher, about 70 mV, zeta potential measurements 
throughout the study at both 4°C and 25°C. Inversely, F,4 measured near neutral at both 
temperatures throughout the study beyond the final Day 35 reading which measured a 
zeta potential of nearly 70 mV. This strong fluctuation in measurements could be 
attributed to a drastic change in surface charge and thus colloidal stability against 
aggregation, but more likely an explanation is due again to the high polydispersity and 
sedimentation rate of the F,4 population which can lead to large variations in zeta 
potential measurements. These results again suggest a greater shelf stability and 
consistently definable characteristics of F,3 over F,4. 
 Overall parent peptide was observed in both formulations at the two temperatures 
tested. Qualitatively significant amounts of the three charged states of the peptide were 
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deconvoluted to the monoisotopic weight of the parent peptide (not shown). Decreases in 
peptide associated peak area, particularly for formulations stored at 25°C, indicate a loss 
of total mass, but particular oxidative or hydrolytic degradants could not be identified 
using this analysis in the immediate vicinity of the peptide associated peak. This is 
further supported by the overall loss in spectra intensity from the parent peptide (Figure 
13), with further decreases found within the 25°C samples. This analysis indicates an 
overall presence of parent peptide within both formulations after 40 days of storage at 
4°C and 25°C, but apparent increases in the remaining parent peptide in the formulations 
stored at 4°C point to it’s inherent optimal storage temperature. 
 
5.4 Human ex-vivo peptide follicle penetration analysis 
 Following analysis of a single application of both F,3 and F,4 for 30 minutes, 
confocal images presented in Figure 16 suggest insignificant amounts of murikal 
penetrated into the human dermis and follicle. However, no peptide was visualized at the 
surface of the tissue as seen previously in confocal images of treated mice (Figure 4 and 
Figure 7). This lack of unpenetrated peptide at the tissue surface suggests a possibility of 
inadequate visualization, which is supported by the change from the 100% (m/m) 
labeled-peptide applied to the tissues in Figure 4 and 7 to the 3 % (m/m) applied to the 
human tissue in Figure 16. Application of 100% (m/m) labeled-peptide as done in 
previous studies is thus needed to unequivocally confirm the failure of these formulations 
to deliver the therapeutic peptide to the follicle of human tissue. In addition, poor nuclear 
staining of the human tissue seen in Figure 16 as compared to previous studies needs to 
be addressed either with additional analysis of cryosectioned tissue, optimization of 
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DAPI nuclear staining time, or if significant cell death occurred in the time following 
excision and treatment, alterations in tissue handling or equilibration. 
 
6. Conclusions 
 In this study, follicular delivery of a promising peptide therapeutic was 
accomplished through a liposomal topical formulation. The formulation’s ability to 
partition peptide into the dermis and localize within the follicles was visualized using 
confocal microscopy in a mouse model. Tremendous therapeutic potential was shown in 
a mouse model, where mice treated with murikal in a liposomal vehicle showed a clear 
increase in hair growth rate and density over a two week period compared to the leading 
treatment standard, daily topical murikal applications. Additional formulations were 
developed and tested to optimize these effects and two were advanced into a month-long 
stability trial. Although F,4 showed generally reliable stability characteristics, F,3 was 
determined to be the optimal particle in that it efficiently encapsulated the peptide, had 
ideal particle size and narrow distribution, and had stable highly charged particle surfaces 
that counter flocculation. F,3 stored at 4°C also showed an optimal chemical stability of 
peptide according to mass spectra data. Translation of the efficient topical delivery of the 
murikal peptide to human hair follicles was not shown conclusively in the first trial. 
 
7. Future Work 
 Confirming the translatability of the successful delivery of the murikal peptide to 
human follicles is critical to the eventual therapeutic use of this peptide, particularly 
within a liposomal formulation. If the peptide can be visualized at or near the levels seen 
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in the murine confocal studies, further optimizations of the formulation can be made 
including addition of thickening agents, preservatives and fragrances to make a more 
marketable product prior to in vivo human efficacy trials. Additional studies should also 
be performed utilizing ZnCl within the formulation as the presence of this metallic ion 
has previously shown increased bone mineralization activity, which may translate in its 
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